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A B S T R A C T
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive impairments. The classical
symptoms of the disease include gradual deterioration of memory and language. Epidemiological studies in-
dicate that around 25–40% of AD patients have sleep-wake cycle disturbances. Importantly, a series of studies
suggested that the relationship between AD and sleep disturbance may be complex and bidirectional. Indeed,
accumulation of the extracellular neuronal protein amyloid-beta (Aβ) leads to altered sleep-wake behavior in
both mice and humans. At the same time, disturbances of the normal sleep-wake cycle may facilitate AD pa-
thogenesis. This paper will review the mechanisms underlying this potential interrelated connection including
locus coeruleus damage, reductions in orexin neurotransmission, alterations in melatonin levels, and elevated
cytokine levels. In addition, we will also highlight how both the development of AD and sleep disturbances lead
to changes in intracellular signaling pathways involved in regulating neuronal plasticity and connectivity,
particularly extremes in cofilin phosphorylation. Finally, current pharmacological and nonpharmacological
therapeutic approaches will be discussed.
1. Introduction
In 2015 more than 47 million people worldwide were affected by
Alzheimer's disease (AD) and other forms of dementia, and according to
the World Health Organization the number is expected to rise to ap-
proximately 150 million by 2050. Clinically, this form of dementia is
hallmarked by cognitive decline, learning and memory problems, and
personality disorders [1]. AD negatively impacts both life quality and
expectancy [2]. AD is also one of the most common progressive neu-
rodegenerative disorders, associated with irreversible degeneration of
the brain [3]. It takes many years for AD to progress from mild cog-
nitive impairments (MCI) to advanced dementia [4]. However, the first
(positron emission tomography) (PET)-based detectable pathology of
the disease occurs about 15 years before any cognitive symptoms ap-
pear, a period referred to as preclinical AD [4]. To date, no treatments
exist despite over a hundred agents being tested in phase I and II
clinical trials, which act as either disease-modifying therapies or
symptomatic cognitive enhancers [5]. Because of the increase in human
longevity, the disease has become a major health and economic chal-
lenge worldwide [6]. As a result, major efforts are undertaken to
identify markers and symptoms to detect AD in its earliest stages.
The neuropathological diagnosis of AD is quite often not confirmed
until postmortem, diagnosed by characteristic cortical degeneration
shown on MRI/CT scans, and determined by the presence of neurofi-
brillary tangles (NFTs) and amyloid-β (Aβ) plaques in neocortical and
subcortical regions of the brain [7,8]. NFTs are composed of highly
phosphorylated forms of the tubulin-associated unit protein (tau) [9].
As indicated by correlational PET scan studies, the accumulation of
NFTs and tau phosphorylation are associated with neuronal dysfunction
and cognitive deterioration in AD [9]. The occurrence of these neuro-
pathological hallmarks is most prominent in brain regions essential for
cognitive function such as the entorhinal cortex and hippocampus [10].
The second main feature in AD pathogenesis is the composition of
strings of Aβ peptides that can form beta sheets. These sheets can then
accumulate further to form Aβ plaques [7]. Aβ plaques occur in the
brain during the earliest stage of preclinical AD [11,12]. The Aβ pla-
ques can be detected in humans by PET [13], and evaluated in cere-
brospinal fluid (CSF). Other hallmarks like tau aggregation into in-
tracellular NFTs, synaptic dysfunction, neuronal loss, and cognitive
impairment have all been correlated with Aβ accumulation [11,12]. In
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fact, due to a series of harmful risk factors, which we will describe
below, Aβ can aggregate and start the progression of the AD [14].
The risk factors of AD partly depend on the form of the disease.
There are currently two known forms of AD: the most common late-
onset AD (LOAD) and early-onset AD (EOAD), the latter occurring in
around 1% - 6% of all cases [15]. LOAD is characterized by an age
higher than 65 years, whereas EOAD ranges from 30 years to 65 years
[15]. Genetically, AD can be distinguished into familial form and
sporadic form [15]. The familial AD is associated with amyloid APOE
genotype and genetic alterations in genes including amyloid precursor
protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) [16].
Sporadic AD, which accounts for over 90% of all AD patients, is a
multifactorial disease resulting from a combination of genetic and en-
vironmental factors [17]. The main factor in the sporadic form is age
[17].
Interestingly, disturbed sleep is another factor of importance that
can accelerate AD pathology [18,19]. For example, amyloid plaques
and tau tangles are also commonly found in brain regions critical for the
regulation and modulation of the sleep-wake cycle, including locus
coeruleus, hypothalamus, and the cortical layers [20]. Importantly, the
connection between AD pathogenesis at the level of Aβ and the dis-
ruption of the sleep-wake cycle is thought to be reciprocal [19]. Indeed,
even a single night of sleep deprivation elevates Aβ levels in the human
brain [21]. This clinical evidence is biologically backed up by rodent
students showing that chronic sleep restriction in AD mouse models
leads to elevated Aβ levels in interstitial fluid [22], whereas chronic
sleep deprivation leads to Aβ accumulation [23]. Because loss of sleep
has become a common feature of our modern society, it may be an
increasingly important risk factor accelerating the development of AD.
For this reason, the current review will describe recent work under-
scoring the potential interrelationship between disrupted sleep and the
development of AD. It will also describe some of the potentially un-
derlying molecular mechanisms and related therapeutic strategies
(Fig. 1).
2. Alzheimer pathology and sleep wake cycle disturbances
To understand how AD and poor sleep interact with one another it is
important to understand the basic properties of the two common sleep
stages: rapid eye movement (REM) and non-rapid eye movement
(NREM). In humans NREM sleep can be subdivided into three stages:
N1, N2 and N3 [24]. During the N1 and N2 stage, EEG background
consists of low amplitude and high-frequency waves, which gradually
progress to high voltage and low frequency waves during the N3
[24,25]. The latter stage is also known as slow wave sleep (SWS) [24].
Further, NREM sleep is associated with behavioral quiescence, and a
general decrease of synaptic activity [24]. REM sleep is characterized
by low amplitude and high-frequency EEG background similar to the
awake state. For this reason, REM is also called paradoxical sleep [24].
Despite the reports that a large proportion of the patients perceive
their sleep quality as satisfactory [26,27], approximately 25–40% of all
patients with AD show impairments of sleep and circadian rhythms.
Specifically, most of the AD patients have an increased latency to fall
sleep and experience more frequent nocturnal awakenings leading to
increased wakefulness at night [28,29]. The latter observation could
very well relate to the in parallel reported daytime sleepiness [28,29].
Even individuals with the early hallmarks of AD show a decline in the
duration of both REM and NREM sleep [30]. Most studies have reported
similar decreases in REM sleep duration or percentages, although such
changes were not observed in every study [31–33]. Regarding NREM
sleep, alterations in slow-wave sleep and slow-wave activity have been
observed in patients with early AD [34] and as such have been pro-
posed as a potential biomarker to detect the early stages of AD [35]. For
a comprehensive overview of specific EEG alterations during different
stages of sleep see the recent report by Winsky-Sommerer and collea-
gues [25]. Finally, sleep disorders such as insomnia and sleep apnea are
commonly observed in AD patients [28,29].
Examining the mechanisms underlying sleep phenotypes in AD is
challenging, due to experimental limitations [36]. Nevertheless, cor-
relative studies use actigraphy, a noninvasive method to assess rest and
activity cycles, showed that cognitively normal individuals with Aβ
deposition (detected by PiB PET imaging), have an increased nap fre-
quency and decreased sleep efficiency in comparison with individuals
without Aβ plaques [37]. It is suggested that those individuals with Aβ
deposition have preclinical AD, and cognitive symptoms will develop in
time [37]. Using (PET-scan in combination with amyloid imaging
traces, Spira et al. indicated that older individuals with a shorter sleep
duration were more likely to have Aβ depositions in cortical layers
including the precuneus, the portion of the superior parietal lobe in-
volved in memory function [38]. It is important to note, however, that
some individuals with high loads of Aβ do not have any memory
complaints or show neuronal degeneration. The latter may be a result of
compensatory factors or potentially through an alternative mechanism
through which cognitive capacity is maintained (for discussion see
[39]).
Because the neural circuits and neurotransmitters responsible for
sleep regulation are highly conserved between mammals [36], experi-
mental animal models are widely used to understand associations be-
tween sleep disturbances and AD [40]. From these studies, a direct link
between AD pathology and sleep disturbances was inferred using ge-
netically engineered mice expressing amyloid and/or tau aggregates in
the brain [41,42]. For example, in mice expressing APP, known as
Swedish mutation Tg2576 line, accumulation of amyloid plaques was
detected in brain regions critical for sleep/wake regulation, leading to
sleep and circadian rhythm abnormalities [41–43]. A hallmark of re-
covery sleep following sleep deprivation is an increase in delta (1-4 Hz)
power during non-REM sleep. Such a physiological response during
recovery sleep is absent in APP mice, underscoring the affected sleep
homeostasis in the mutant mice [42]. Furthermore, at 22 months of age
(equivalent of approximately 65 years of age in humans), time-of-day-
dependent modulation of sleep was blunted and the percentage of REM
sleep was reduced in the same animals [42]. Even at the age of
12 months (equivalent of 40 years of age in humans), these mice al-
ready exhibited stage-dependent decreases in both theta and delta
power, and shifts in the power spectra towards higher frequencies [43].
Also, APP/PS1 transgenic mice show an increase in wakefulness and
reduced sleep time as early as 6 months of age. These behavioral phe-
notypes are accompanied by Aβ plaque formation in the hippocampus
and neocortex [44]. At 9 months of age, plaque formation was observed
Fig. 1. The potential relationship between sleep disturbances and the devel-
opment of Alzheimer's disease.
Multiple signaling mechanisms, affect both sleep homeostasis and quality as
well as the development and progression of Alzheimer's disease (AD). Because
of the potential bidirectional interrelationship between poor sleep and pro-
gression of AD, misregulation of these signaling mechanisms may not only di-
rectly accelerate the development of AD, which indirectly affects sleep quality.
It may also affect sleep hygiene directly and through these mechanisms in-
directly further accelerate the further development of AD.
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throughout the brain leading to an even more prominent disruption of
the sleep-wake cycle with significantly increased wakefulness and de-
creased REM and NREM sleep [44]. Likewise, triple knock-in mice,
generated by Platt and colleagues [45], were designed by targeted in-
sertion of human amyloid and tau transgenes and crossed with an ex-
isting presenilin mutant mouse line. The triple transgenic mice ex-
pressed intra-neuronal amyloid deposits and hyperphosphorylated tau
in hippocampus and cortex starting from 6 months of age. In line with
the other models, the triple mutant mice exhibited enhanced wakeful-
ness alongside with reduced NREM sleep, increased sleep fragmenta-
tion, and higher delta power during wakefulness and REM sleep. These
phenotypes preceded deficits in hippocampal synaptic plasticity and
memory formation, all emerging at approximately 12 months of age.
Using a different AD mouse model harboring three mutations, including
APP, PS1, and tau, Manaye and colleagues found that the age-related
loss of noradrenergic neurons was observed in the locus coeruleus, a
region critically responsible for orchestrating normal wakefulness [46].
Altogether, these studies show that the development of Alzheimer-like
pathologies in murine animal models are associated with prolonged
wakefulness, decreased sleep, and sleep quality (e.g. alterations in sleep
architecture/ homeostasis). Together, the data from clinical studies in
AD patients and from animal models of AD pathology underscore that
Aβ deposition affects both sleep quality and duration and that specific
sleep disturbances might be used as a potential biomarker to detect
early AD pathology. In the next paragraphs, we will describe studies,
which support evidence for a role in sleep-wake disturbances and sleep
loss and the development of AD pathogenesis.
3. Sleep loss exacerbates AD pathology in animal models and
humans
In the previous paragraphs, we described work in humans and an-
imal models indicating that Aβ accumulation in the brain may affect
both sleep duration and sleep quality [38,41,42,44–47]. However, sleep
disturbance in turn may exacerbate the development of AD pathology.
Indeed, a first hint that sleep and wakefulness influence the levels of
soluble Aβ and plaque formation was obtained from animal studies.
Kang et al., assessed the levels of soluble Aβ in the brain interstitial
fluid (ISF) during the sleep-wake cycle in the APP (Tg2576) transgenic
mouse model [22]. Mice were kept under standard light/dark (12 h/12
h) conditions and a diurnal Aβ pattern was observed [22]. Specifically,
they found that the levels of soluble Aβ in the brains were around 25%
higher in the dark phase (i.e. the period in which mice spend the ma-
jority of the time awake) than in the light phase (i.e. their inactive
phase) [22]. Strikingly, the formation of amyloid plaques increased by
two-fold, when sleep was disrupted for 4 h every day for 21 days [22].
These findings were replicated in two other frequently used Alzheimer
mouse models [22]. Finally, using almorexant, an orexin receptor an-
tagonist, to increase sleep time in mice, the authors found that Aβ
plaque formation significantly reduced as a result of increased sleep
time [22]. This elegant set of experiments suggests a direct relationship
between the sleep-wake cycle, soluble Aβ, and Aβ plaque formation.
In human studies, a diurnal Aβ pattern in CSF was also observed
[48]. As reported in the rodent studies, the soluble Aβ levels in CSF
were higher during the waking phase, and lower during sleep [48].
While the levels fluctuated in young participants in a circadian fashion,
they decreased in older participants with and without amyloid de-
position [48]. Individuals with amyloid deposition lacked diurnal var-
iation in the levels of soluble Aβ, especially in the level of Aβ42 [48].
Furthermore, it is interesting to note that individuals with a PSEN1 or
PSEN2 mutation but without Aβ aggregates have a normal diurnal
variation of Aβ in CSF, while diurnal variation was disturbed in those
expressing Aβ aggregates [48]. Furthermore, using PET and 18F-flor-
betaben to measure brain Aβ burden in the brains of healthy controls,
Shokri-Kojori and colleagues showed that Aβ accumulation was ob-
served in the right hippocampus and thalamus following just a single
night of sleep deprivation [21]. Related to these observations, Heneka
and colleagues [49] examined in transgenic mice whether plaque for-
mation was affected by experimentally-induced locus coeruleus de-
generation, a common hallmark of early AD pathogenesis that di-
minishes cortical noradrenergic innervation [50]. The authors observed
significantly more plaque formation in mice following early locus
coeruleus degeneration than in age-matched control mice. Because the
locus coeruleus region contributes to the regulation of the sleep-wake
cycle, these findings suggest that disruption of the normal sleep-wake
cycle may directly contribute to Aβ deposition [49]. In addition to these
studies in which the indirect impact of sleep disturbances (by means of
locus coeruleus damage) on the development of AD pathologies was
assessed, many laboratories have examined the direct impact of sleep
deprivation on the development of AD pathologies in rodent models.
For example, Chen et al showed that as little as 2 to 4 days of sleep
deprivation using the flowerpot method (a method that omits REM
sleep and some non-REM sleep) not only causes cognitive impairments
[51]. It also leads to increased levels of Aβ peptide. Likewise, hi-
bernation studies in ground squirrels revealed that Aβ could reversibly
be formed during periods of sleep loss-hibernation [52]. A likely ex-
planation for the increase in Aβ peptide was the observed parallel
elevation of the APP-cleaving enzyme 1 (BACE1, β-secretase). Together
with the absence of changes in the levels of Aβ-degradation enzymes,
this may ultimately lead to elevated Aβ42–44 deposits [51].
In addition to examining the direct impact of sleep deprivation on
the development of AD phenotypes in rodents, a few laboratories have
attempted to replicate such studies in humans. For example, a study
including 26 cognitively healthy male subjects, indicated that even a
single night of sleep deprivation significantly increases the levels of
Aβ42 in CSF [53]. In addition, the authors observed that the levels of
Aβ42 decreased by 6% if sleep was normalized [53]. In line with these
observations, others have reported that 36 h of sleep deprivation lead to
a 25–30% increase in CSF Aβ38, Aβ40, and Aβ42 concentration as a
result of increased overnight production of Aβ [54]. Recent work using
a PET approach by Shokri-Kojori and colleagues indicated that even a
single night of sleep deprivation is sufficient to elevate Aβ levels,
especially in the right hippocampus and thalamus [21].
An important question that remained unanswered was which aspect
of sleep modulates Aβ levels in the human brain. Jiu and colleagues
addressed this question by specifically disrupting slow-wave activity in
healthy volunteers [55]. They found that the specific disruption of slow
waves correlated with an increase in CSF Aβ40 without affecting total
protein, tau, or hypocretin levels. This effect was not correlated with
sleep duration or sleep efficiency. Interestingly, the authors also ob-
served that poor home sleep quality (assessed using actigraphy) is as-
sociated with increases in CSF tau. Related to these observations, the
lab of David Holtzman recently showed that tau seeding and spreading
are influenced by the sleep-wake cycle and sleep deprivation. ISF tau in
mice and CSF tau in humans were elevated following sleep deprivation.
Even more striking is the finding that chronic sleep deprivation in-
creased tau pathology spreading [56]. These findings underscore the
importance of unraveling the molecular underpinnings by which sleep
loss and sleep disturbance facilitate the tau pathology.
In summary, the level of soluble Aβ and tau are fluctuating in a
diurnal pattern with levels rising during wakefulness and decreasing
during sleep. Disrupted sleep and sleep loss can lead to increased Aβ
accumulation in both humans and rodents with poor sleep hygiene even
leading to increased tau levels in the CSF. The underlying mechanisms
connecting sleep-wake cycle disturbances and AD pathogenesis are still
under investigation [57], although the aforementioned studies suggest
that a dysregulation of Aβ kinetics may facilitate the AD pathogenesis
in the sleep-deprived brain.
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4. Potential molecular mechanisms underlying the relationship
between disturbed sleep and AD pathology
Given the potential importance of disturbed sleep in the develop-
ment and progression of AD, it is important to get a better under-
standing of the neurobiological, cellular and molecular mechanisms
underlying the complex relationship between sleep and AD pathology
[58]. Several molecular underpinnings have been described that may
explain this potential relationship between sleep-wake cycle and AD
pathogenesis. In the next set of paragraphs, we will discuss several of
these potential mechanisms.
One possible mechanism is that oscillations in neuronal activity as
observed during specific sleep stages and wakefulness lead to fluctua-
tions in Aβ concentrations. At the neuronal level, non-REM sleep is
associated with the quiescent state [22]. PET imaging can successfully
be used to assess the cerebral metabolic rate during specific sleep/wake
stages by measuring glycolysis levels of individuals during awake, REM,
and non-REM state [59,60]. Glycolysis was similar in awake and REM
stages, whereas it was decreased by 43.8% during the SWS stage
[59,60]. These findings indicate that the differences between awake
and deep-sleep stages are in part associated with the level of neuronal
activity [59,60]. Indeed, in awake and REM stages, cortical neurons
continuously fire, which leads to low amplitude and high-frequency
EEG background [61,62]. In contrast, during the SWS stage, more high
amplitude and low-frequency waves in EEG are detected due to neural
oscillation between silent periods of hyperpolarization and depolar-
ization [61]. Aβ is released into the brain ISF during neuronal firing or
synaptic activity [63], suggesting that increased neuronal activity leads
to a higher concentration of Aβ in ISF [63]. Because neurons spend
most time in their ‘silent stage’ during SWS, it is believed that they
release less Aβ at this stage, whereas the opposite effect is expected
during other sleep or awake stages [63]. Indeed, Aβ levels are lower
during sleep in both the ISF of mice and CSF of humans [22,42].
The aforementioned mechanism suggests that sleep may influence
Aβ production through neuronal activity. However, one of the other
mechanisms contributing to the AD pathogenesis is a failure to clear Aβ
from the brain [4]. Different clearance systems are known to be re-
sponsible for soluble Aβ elimination from the brain [64]. Several rodent
studies suggested, that around 75% of the extracellular Aβ is removed
from the brain by the blood-brain barrier transport system, whereas
merely 10% by means of the ISF bulk flow system [65]. However, the
notion that the ISF bulk flow system only contributes to a minor portion
of the Aβ removal was challenged by others. Using two-photon imaging
studies, they showed that a specialized ISF bulk flow system, known as
glymphatic system, which depends on astrocytic aquaporin-4 (AQP4)
water channels, is responsible for more amounts of Aβ clearance than
previously thought [66,67]. In the brain, this system channels ISF
through astrocytes into the peripheral lymphatic system [67]. Iliff and
his group injected radiolabeled Aβ into the mouse striatum, which al-
lowed them to assess the activity of the clearance system. The authors
showed that the rate by which this radioactive Aβ probe was removed
from the brain was two times higher in control animals compared to
AQP4 knockout mice, underscoring the importance of the AQP4 ex-
pressed in astrocytes for Aβ clearance [66].
Because sleep is one of the factors affecting the glymphatic system
[68], it is interesting to speculate that the clearance of Aβ is higher
during sleep and that, as a result, the sleep-wake cycle may influence
the glymphatic clearance of Aβ [69]. Using two-photon imaging, Xie
et al compared the level of cortical CSF influx during wakefulness,
anesthesia, and sleep in mice [69]. Both sleep and anesthesia lead to a
60% increase in the interstitial space, indicating that the exchange
between CSF with ISF during both sleep and anesthesia is altered [69].
As such, these results support the hypothesis, that brain clearance of Aβ
(and other molecules) is indeed increased during sleep [69].
Orexin critically contributes to the organization of sleep-wake cy-
cles. Orexin is a neuropeptide produced in the hypothalamus [70], and
its levels in- and decrease during respectively wakefulness and REM
sleep. Because impairments in the orexinergic system alter the dy-
namics of Aβ and tau proteins, orexin is also considered a possible
mediator of the disrupted sleep-wake cycles in AD patients [70]. In-
deed, intracerebroventricular administration of orexin in mice leads to
increased wakefulness and significantly higher Aβ levels in the brain
ISF [22]. Furthermore, application of an orexin receptor antagonist
over a period of 24 h showed significantly reduced levels of Aβ [22].
Moreover, reduced plaque formation was observed, when the same
antagonist was administered for an additional 8 weeks [22]. Based on
these observations, Kang and colleagues hypothesized that orexin not
only promotes wakefulness, which in turn is related to higher levels of
Aβ in the brain, it also has a direct effect on Aβ dynamics [18,22].
To understand the molecular underpinnings mediating these effects,
additional animal studies were performed to determine whether dis-
ruptions of the sleep-wake cycle or orexin-mediated wakefulness are
causally related with abnormal Aβ metabolism. Using APP/PS1, the
Holtzman lab examined whether orexin release directly or indirectly
through the modulation of sleep affected development of AD pathology.
Genetic ablation of the orexin gene in the APP/PS1 mutant mice re-
duced the amount of Aβ pathology in the brain and in parallel led to an
increased sleep time. Furthermore, increasing wakefulness by restoring
orexin receptor expression in the brains of APP/PS1 orexin knock-out
mice or application of sleep deprivation elevated the amount of Aβ
pathology in the brain [18]. Altogether, their important findings sup-
port the idea that orexin, through its role in wake regulation and
neuronal activity, impacts the development of Aβ pathology [18]. As
such, the orexinergic system remains a promising target for human
studies to interrogate the relation between sleep and Aβ pathology in
preclinical stage AD patients.
Melatonin is thought to be involved in regulating human sleep, and
loss of it can lead to disturbances of both the sleep-wake cycle as well as
circadian rhythms. Because the levels of melatonin are more than ten-
fold higher during darkness [71], it is often referred to as a “dark”
hormone. Melatonin is produced by the pineal gland [72] and is asso-
ciated with neurodegenerative diseases including AD due its neuro-
protective effects [73–75]. Indeed, administration of melatonin in mice
decreased the production of Aβ [76]. Melatonin directly regulates the
metabolism of APP, leading to lower levels of Aβ production [76].
Importantly, decreased levels of CSF melatonin were observed in pa-
tients carrying the ApoE4 allele (one of the main risk factors of AD)
[76]. In parallel to the disturbances in the sleep-wake cycle, decreased
levels of CSF melatonin are already detected during the preclinical
stage of AD [77,78]. Altogether, these interesting findings corroborate
the idea that the reduction of melatonin may indeed contribute to
plaque formation by increasing Aβ levels in the brain [76], while in
parallel negatively impacting the sleep-wake cycle. It is unclear, how-
ever, whether melatonin merely independently modulates both pro-
cesses in parallel or whether the progression of AD and poor sleep
quality by means of changed melatonin levels is directly interrelated.
The association between sleep deprivation and inflammatory re-
sponses has also been discussed in various conditions including AD
[79]. The most frequently used approach to examine the relationship
between sleep and inflammatory responses is by means of applying
sleep deprivation. For example, total sleep deprivation for four nights
increases levels of C-reactive protein (CRP), interleukin-6 (IL-6) and
tumor necrosis factors (TNF), with the increases of TNF already emer-
ging after as little as two nights [80–82]. For a comprehensive overview
of the impact of sleep deprivation on innate immunity see [83]. A
second approach that has been used to study the link between sleep and
inflammatory processes is by studying how inflammatory cytokines
behave in insomnia [79]. Motivala et al. summarized that more chronic
sleep disturbances also increases the expression of inflammatory cyto-
kines like IL-6, CRP, and TNF-α in humans [84]. Furthermore, Chen
et al. indicated that patients with mild or moderate stages of AD have
increased levels of IL-1β and TNF-α [85]. In Alzheimer mouse models,
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high levels of TNF-α are associated with increased Aβ production and
decreased Aβ clearance. In contrast, TNF-α neutralization leads to op-
posite effects [86]. Inhibition of TNF-α signaling before the Aβ plaque
formation, prevents hyperexcitability of glutamine synapse which re-
lates with cognitive decline [87]. However, there is no evidence that
TNF-α levels are increased at least in the preclinical stage of AD
[88,89].
Another hypothesis related to AD and inflammation, is that the re-
ciprocal association between sleep and immune responses is promoted
by low-grade inflammation in aging [79]. The low-grade inflammation
is characterized by multiple factors such as increased production of
reactive oxygen species, and elevated levels of proinflammatory cyto-
kines, like IL-6 and TNF [79]. Bjurstrom et al. indicated that increased
expression of TNF-α and IL-6 correlates with better sleep maintenance
and higher SWS percentage in older adults, while lower expression of
proinflammatory cytokines were observed in the morning [90]. A
period of sleep deprivation is normally accompanied by a typical
homeostatic rebound with an increase in SWS and slow-wave activity.
In elderly people, however, such a homeostatic rebound was reported to
be absent [91]. As a result, long-term changes in sleep may elevate the
amount of circulating proinflammatory compounds in the morning
thereby facilitating inflammation [92]. At the same time, such in-
creased levels of inflammatory markers may inhibit further activation
of immune cells, which undermines a relationship between sleep
maintenance and -depth with evening and morning fluctuations in cy-
tokines production [93]. In line with this hypothesis, it should be noted
that elderly people do not exhibit the increase in inflammatory cytokine
production, while this is observed in young adults following acute sleep
restriction [94].
In turn, proinflammatory cytokines as well as Aβ in AD brains are
linked to increased levels of cytoplasmic rod-shaped bundles of fila-
ments that are composed of ADF/cofilin-actin and conveniently called
rods [95]. Cofilin, the major ADF/cofilin isoform in mammalian neu-
rons, severs actin filaments at low cofilin/actin ratios and stabilizes
filaments at high cofilin/actin ratios. Cofilin's phosphoregulation is a
downstream target of many transmembrane signaling processes and its
misregulation in neurons has been linked to AD in rodent models [96].
Cofilin is activated by dephosphorylation and is thought to be oxidized
in stressed neurons bundling cofilin-actin filaments into stable rods.
Rods form within neurites causing synaptic dysfunction by sequestering
cofilin, disrupting normal actin dynamics, blocking transport, and ex-
acerbating mitochondrial membrane potential loss [95,97,98]. Inter-
estingly, recent work indicated that hippocampal cofilin activity is
elevated following sleep deprivation [99]. Suppressing cofilin activity
selectively in hippocampal neurons was sufficient to prevent the cog-
nitive deficits and plasticity impairments associated with sleep depri-
vation, underscoring an important and causal role for cofilin signaling
in the phenotypes associated with sleep loss. In this way, misregulation
of cofilin signaling as a result of sleep deprivation may exacerbate the
progression of AD at the molecular level. Cofilin signaling and its up-
stream signaling pathways may therefore also be valuable targets to
combat the progression of AD as a result of sleep disturbances and sleep
loss (Fig. 1).
5. Current therapies
At present, there are very limited therapies for AD patients with
reported disturbances of their sleep-wake cycle [36]. Therapeutic ap-
proaches with emphasis on sleep hygiene may be a fruitful approach to
slow the progression of AD. For this reason, it is important to further
elucidate the interrelationship between AD and poor sleep quality,
which eventually might contribute to new therapeutic approaches [58].
In order to fully understand the therapeutic potential of sleep therapy,
longitudinal sleep studies should include patients with preclinical AD or
individuals with genetic mutations, which are associated with a familial
form of AD [100].
Current nonpharmacological strategies focus in some cases on
“sleep hygiene” [101,102]. Recommendations for patients include
limitations of caffeine and alcohol usage, keeping regular sleep-wake
times, as well as avoidance of light exposure during the night time
[101,102]. A major problem for institutionalized patients is insufficient
light exposure during daytime [101,102]. A study by Shochat et al.,
indicated that the average time of natural sun light in a nursing home
was as little as 1 min [102]. Unfortunately, the effect of morning bright
light treatment for rest-activity disruption in AD patients seemed rather
modest. Only in subjects with the most impaired rest-wake activity, a
positive and significant impact of a brief (one hour) light treatment was
observed [103].
The number of available pharmacological strategies focusing on
enhancing sleep quality to combat AD are unfortunately limited [36].
Melatonin, trazodone, and ramelteon were tested in randomized studies
as possible drugs to improve sleep quality [104]. Patients with mod-
erate or severe AD stages were included in melatonin and trazodone
trials, and mild and moderate stages patients were included in ra-
meltozon studies [105–107]. Unfortunately, melatonin and ramelteon
treatment did not lead to increased quality of sleep in patients
[105–107]. In the trazodone studies, improvements were observed in
sleep efficiency and total sleep time, but no changes were reported for
daytime sleep [108]. Another interesting class of drugs with therapeutic
potential that is linked to both AD and sleep are the type 4 phospho-
diesterase inhibitors (PDE4 inhibitors). PDE4 inhibitors have shown to
be promising cognition enhancers in clinical studies [109,110] and
animal models [111]. Indeed, treatment with the PDE4 inhibitor roli-
pram was shown to make synapses and neurons more resistant to the
damaging effects of Aβ, although the protective effects seem to be
working through pathways bypassing Aβ itself [112,113]. In addition,
more recent work highlighted the possibility that rolipram may also
promote the clearance of aggregated tau [114]. Moreover, attenuated
cAMP signaling, as a result of elevated activity of the PDE4 family,
seems to be a causal factor in the detrimental effects of sleep loss on
memory function [99,115–118]. Specifically, sleep loss upregulates the
levels of PDE4A5 isoform in the hippocampus [115], which facilitates
the dephosphorylation and activation of cofilin [99,117]. The increase
in cofilin activity ultimately leads to spine loss, impairments in synaptic
plasticity and memory storage [99,117]. Because suppressing cofilin
function is sufficient to prevent these memory deficits [99,117], and the
direct interaction between cofilin and PDE4 signaling [99,117,119],
PDE4 inhibitors may be particularly promising as potential therapeutic
tools to combat the impact of both sleep deprivation as well as AD. As
such, therapy for AD patients with sleep disturbances focusing on PDE4-
cofilin signaling still remains a promising area for future therapeutic
development.
6. Conclusions
AD is the most common cause of dementia and includes around
50–70% of all dementia cases [3]. Around 50% of people by age 85
suffer from AD, since the risk of the disease highly increases with age
[3]. Clinically, AD is associated with a gradual decline in cognitive
function. It takes many years of progression from mild cognitive
symptoms to develop severe dementia [4]. In the preclinical stage of
AD, there are no cognitive symptoms yet as they appear only around
15 years later [4]. However, an increased level of Aβ peptide, as well as
plaque formation, is already detected. Interestingly, during the pre-
clinical AD, disruption of sleep-wake cycles is often observed. Indeed,
around 25–40% of AD patients suffer from sleep disturbances, including
reduced sleep efficiency, sleep fragmentation, and increased daytime
napping. Earlier, multiple studies suggested that disrupted sleep-wake
cycles are one of the potential risk factors for AD [58]. However, on-
going research underscored the idea that an impaired sleep-wake cycle
is not only a result of the AD pathology, it in fact also exacerbates the
AD pathology. Indeed, studies in both humans and animal models, have
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indicated that accumulation of Aβ negatively impacts sleep quality.
Furthermore, levels of soluble Aβ increase following sleep deprivation,
which results in exacerbation of AD pathology. All these studies suggest
that there are multiple mechanisms that impact both AD pathology and
sleep-wake cycle. Decreased neuronal activity, altered activity of the
glymphatic system affecting the transport of Aβ out of the brain,
changed melatonin, orexinergic, cAMP-PDE and cofilin signaling, as
well as increased inflammatory responses in the brain are potentially
critical mechanisms associated with AD pathology and alterations in the
sleep-wake cycle. Further studies are necessary in order to fully eluci-
date the underlying mechanisms, which explain the associations be-
tween altered sleep-wake cycles and Aβ accumulation. The outcome of
such studies may clarify how sleep interacts with the AD pathogenesis,
and ultimately dictate how modulation of specific pathways can be used
to target both poor sleep hygiene and AD pathogenesis.
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